for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion



TGCT is a rare disease that is difficult to manage, surgical resection is the primary treatment currently available. To date no disease registry exists and there is little data available detailing the management of patients with diffuse TGCT, the burden of diffuse TGCT for patients (including pain, joint stiffness, swelling, reduced mobility and quality of life) or the economic impact of diffuse TGCT. This study aims to collect data by an observational disease registry involving no intervention to the patient or changes to investigators treatment decisions.

Official Title

A Disease Registry for Patients With Tenosynovial Giant Cell Tumors (TGCT), Also Known as Pigmented Villonodular Synovitis (PVNS) and Giant Cell Tumor of the Tendon Sheath (GCT-TS)


GCT is a rare, benign, but potentially locally aggressive and recurrent disease. Treatment pattern and treatment initiation, continuation or changes are solely at the discretion of the physician and the patient. There will be no attempt to influence the prescribing patterns of any individual treating physician. All medication will be prescribed in the usual standard of care and will not be provided by the study sponsor. Participation in the study will in no way influence payment or reimbursement for any treatment received by patients during the study. It is the responsibility of the investigator and his study staff to enter all relevant patient data required for this registry in the electronic Case Report Form (eCRF) and in the patients' medical records. Approximately 15 sites from up to 6 European Countries (France, Germany, Italy, The Netherlands, Spain and United Kingdom) and 4 sites from the US are planned to participate. The sites will be specialized sites that treat diffuse TGCT regularly.


Giant Cell Tumors Tenosynovial Giant Cell Tumors Disease registry Routine clinical practice Real World Evidence Giant Cell Tumor of Tendon Sheath


You can join if…

Open to people ages 18 years and up

  • Written informed consent for participation in the study (ICF)
  • Patients with diffuse TGCT (diagnosed histologically) confirmed naïve or recurrent case

You CAN'T join if...

  • None


  • University of California San Francisco
    San Francisco California 94158 United States
  • David Geffen School of Medicine at UCLA
    Los Angeles California 90095 United States


in progress, not accepting new patients
Start Date
Completion Date
Daiichi Sankyo, Inc.
Study Type
Observational [Patient Registry]
Last Updated